Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish Study of Feasibility, Costs, and Implementation

Arms (0)

Primary outcomes (10)

1. measure

   Rates of retention to standard protocol in patients receiving home-based treatment.

   timeFrame

   Through study completion, an average of 20 weeks per patient.

   description

   Retention will be measured as the proportion of patients who remain in the standard home-based treatment protocol until completion of the planned treatment course. The retention rate will be calculated as: Number of patients who complete the planned home-based treatment protocol / Number of patients who initiate home-based treatment × 100. Non-retention is defined as any deviation from the site-specified standard home-based treatment protocol resulting in temporary or permanent interruption of home-based treatment and transition to hospital-based treatment, either temporarily or permanently.

2. measure

   Number and proportion of treatment doses administered at home, administered at the hospital, diverted from home to hospital, or not administered

   timeFrame

   From date of inclusion, up to 20 weeks

   description

   Treatment delivery will be assessed by recording the location of administration for each planned treatment dose via EHJ. Doses will be categorized as: * Administered at home as planned * Administered at the hospital as planned * Diverted from home to hospital, defined as a dose planned for home administration but administered at the hospital * Not administered/missed doses The number and proportion of doses in each category will be calculated relative to the total number of planned treatment doses.